Literature DB >> 12389884

The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis.

M Murphy1, A Loosemore, A G Clifton, F A Howe, A R Tate, S A Cudlip, P R Wilkins, J R Griffiths, B A Bell.   

Abstract

Proton magnetic resonance spectroscopy (1HMRS) provides biochemical information from tissue non-invasively, and has an evolving role in brain tumour diagnosis and management. We present 100 consecutive patients with brain tumours who had single voxel 1HMRS as part of their preoperative investigations. We report the histopathological findings and the diagnostic contribution of spectroscopy in an adjunctive role. On the basis of clinical and radiological information the preoperative diagnosis was unclear or inaccurate in 26 out of 100 cases. The discrepancy was of lesion grade in 17 cases and lesion type in 9 cases. In 6 of 100 patients with brain tumours 1HMRS could have made a significant contribution to the preoperative diagnosis if used as part of the routine assessment. There is therefore a useful role for 1HMRS in the evaluation of intracranial mass lesions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12389884     DOI: 10.1080/0268869021000007687

Source DB:  PubMed          Journal:  Br J Neurosurg        ISSN: 0268-8697            Impact factor:   1.596


  15 in total

Review 1.  [(1)H magnetic resonance spectroscopy (MRS) of the liver and hepatic malignant tumors at 3.0 Tesla].

Authors:  F Fischbach; M Thormann; J Ricke
Journal:  Radiologe       Date:  2004-12       Impact factor: 0.635

2.  Metabolite detection of pancreatic carcinoma by in vivo proton MR spectroscopy at 3T: initial results.

Authors:  X Yao; M Zeng; H Wang; S Fei; S Rao; Y Ji
Journal:  Radiol Med       Date:  2011-11-17       Impact factor: 3.469

Review 3.  A systematic literature review of magnetic resonance spectroscopy for the characterization of brain tumors.

Authors:  W Hollingworth; L S Medina; R E Lenkinski; D K Shibata; B Bernal; D Zurakowski; B Comstock; J G Jarvik
Journal:  AJNR Am J Neuroradiol       Date:  2006-08       Impact factor: 3.825

4.  Neuroradiological assessment of newly diagnosed glioblastoma.

Authors:  Srini Mukundan; Chad Holder; Jeffrey J Olson
Journal:  J Neurooncol       Date:  2008-08-20       Impact factor: 4.130

Review 5.  Novel functional magnetic resonance imaging biomarkers for assessing response to therapy in hepatocellular carcinoma.

Authors:  Z Yuan; W-T Li; X-D Ye; H-Y Zhu; W-J Peng
Journal:  Clin Transl Oncol       Date:  2013-12-20       Impact factor: 3.405

Review 6.  Magnetic resonance spectroscopy in metabolic and molecular imaging and diagnosis of cancer.

Authors:  Kristine Glunde; Dmitri Artemov; Marie-France Penet; Michael A Jacobs; Zaver M Bhujwalla
Journal:  Chem Rev       Date:  2010-05-12       Impact factor: 60.622

7.  Combined MRI and MRS improves pre-therapeutic diagnoses of pediatric brain tumors over MRI alone.

Authors:  Mark S Shiroishi; Ashok Panigrahy; Kevin R Moore; Marvin D Nelson; Floyd H Gilles; Ignacio Gonzalez-Gomez; Stefan Blüml
Journal:  Neuroradiology       Date:  2015-07-04       Impact factor: 2.804

8.  The contribution of magnetic resonance spectroscopy and echoplanar perfusion-weighted MRI in the initial assessment of brain tumours.

Authors:  Nicolás Fayed; Pedro J Modrego
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

9.  The effect of paramagnetic contrast in choline peak in patients with glioblastoma multiforme might not be significant.

Authors:  E C Lima; M C G Otaduy; M Tsunemi; R Pincerato; E F Cardoso; S Rosemberg; P H Aguiar; G G Cerri; C C Leite
Journal:  AJNR Am J Neuroradiol       Date:  2012-07-05       Impact factor: 3.825

10.  Diagnostic accuracy and added value of qualitative radiological review of 1H-magnetic resonance spectroscopy in evaluation of childhood brain tumors.

Authors:  Karen A Manias; Simrandip K Gill; Lesley MacPherson; Adam Oates; Benjamin Pinkey; Paul Davies; Niloufar Zarinabad; Nigel P Davies; Ben Babourina-Brooks; Martin Wilson; Andrew C Peet
Journal:  Neurooncol Pract       Date:  2019-05-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.